Trial Profile
Study to evaluate the safety of rapid infusion of Truxima® (Rituximab biosimilar) in patients who switched from MabThera® or are MabThera® naive
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Dec 2017
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Rheumatoid arthritis
- Focus Adverse reactions
- 20 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology